Disentangling Gendered Cancer Care: Improving Cervical and Breast Screenings for Sexual and Gender Minority PeoplePremiere Date: Wednesday, February 23, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, February 23, 2023
Note: Credit Is No Longer Available
|Don S. Dizon, MD, FACP, FASCO (Moderator)
Professor of Medicine and Professor of Surgery, Brown University
Director, The Pelvic Malignancies Program and Hematology-Oncology Outpatient Clinics, Lifespan Cancer Institute
Head, Community Outreach and Engagement, Legoretta Cancer Institute at Brown University
Director, Medical Oncology and the Oncology Sexual Health First Responders Clinic
Rhode Island Hospital
|Gwendolyn P. Quinn, PhD
Professor and Livia Wan MD Endowed Chair
Department of Obstetrics and Gynecology
New York University Grossman School of Medicine
New York, NY
|Ash B. Alpert, MD, MFA
AHRQ T32 Post-Doctoral Fellow in Health Services Research
Center for Gerontology and Healthcare Research
Department of Health Services, Policy & Practice
Brown University School of Public Health
Across the care spectrum, gender is closely tied to health care, with labels like Women's Health Clinic, Women's Breast Center, Women's Cancer, Men's Cancer, and so on. Sexual and gender minority patients are disproportionately burdened with cancer compared to their cisgender, heterosexual counterparts. These individuals have both similar and unique health care needs related to health-promoting screenings for breast and cervical cancers, yet these patients are faced with significant inequities that may result in either delays in care or a lack of appropriate and sensitive care. Health care professionals (HCPs) have an opportunity to improve care for sexual and gender minority patients through education that increases their medical and cultural knowledge, shifts behaviors and practices, and leads to improved competency of care. A critically important aspect of this shift is addressing the common existing heterosexual and cisgender presumptive care models for patients receiving health-promoting breast and cervical cancer screenings.
This CME Outfitters Live and OnDemand activity will focus on the disparities and unique health care needs of sexual and gender minority people as it aims to raise HCP awareness of the damaging impact of heterosexual or cisgender presumptive clinical environments, language, and interactions, and showcase processes that create an inclusive, culturally relevant, and trusting environment.
At the end of this CE activity, participants should be able to:
- Assess disparities and unique health care needs of sexual and gender minority people related to cancer screening.
- Recognize the impact that a heterosexual or cisgender presumptive care setting has on health-promoting cancer screenings of sexual and gender minority people.
- Integrate processes with HCPs and staff that create an inclusive, culturally relevant, and trusting environment for patients conducive to discussions and receipt of anatomical-based preventive cancer care.
Supported by an educational grant from Merck Sharp & Dohme Corp.
Oncologists, OB/GYNs, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Dizon reports the following financial relationships:
Consultant: DSMB/IDMC activities for AstraZeneca and Clovis Oncology.
Research Institutional Support: Bristol Myers Squibb and Pfizer Inc.
Other financial or material support: Board member for the LGBTQ Cancer Network.
Dr. Quinn reports the following financial relationships:
Consultant: Flo Health, Inc.
Dr. Alpert has no financial relationships to disclose.
The following Peer Reviewer and CME Outfitters staff have no financial relationships to disclose:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).